• Je něco špatně v tomto záznamu ?

Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy

A. Martini, L. Afferi, S. Zamboni, JG. Schultz, C. Lonati, A. Mattei, RJ. Karnes, M. Soligo, A. Stabile, E. Di Trapani, O. De Cobelli, G. Simone, C. Simeone, M. Alvarez-Maestro, G. Gandaglia, A. Gallina, R. Colombo, A. Briganti, F. Montorsi, E....

. 2021 ; 206 (4) : 885-893. [pub] 20210525

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024924

PURPOSE: Presently, major guidelines do not provide specific recommendations on oncologic surveillance for patients who harbor variant histology (VH) bladder cancer (BCa) at radical cystectomy. We aimed to create a personalized followup scheme that dynamically weighs other cause mortality (OCM) vs the risk of recurrence for VH BCa, and to compare it with a similar one for pure urothelial carcinoma (pUC). MATERIALS AND METHODS: Within a multi-institutional registry, 528 and 1,894 patients with VH BCa and pUC, respectively, were identified. The Weibull regression was used to detect the time points after which the risk of OCM exceeded the risk of recurrence during followup. The risk of OCM over time was stratified based on age and comorbidities, and the risk of recurrence on pathological stage and recurrence site. RESULTS: Individuals with VH had a higher risk of recurrence (recurrence-free survival 30% vs 51% at 10 years, p <0.001) and shorter median time to recurrence (88 vs 123 months, p <0.01) relative to pUC. Among VH, micropapillary variant conferred the greatest risk of recurrence on the abdomen and lungs, and mixed variants carried the greatest risk of metastasizing to bones and other sites compared to pUC. Overall, surveillance should be continued for a longer time for individuals with VH BCa. Notably, patients younger than 60 years with VH and pT0/Ta/T1/N0 at radical cystectomy should continue oncologic surveillance after 10 years vs 6.5 years for pUC individuals. CONCLUSIONS: VH BCa is associated with greater recurrence risk than pUC. A followup scheme that is valid for pUC should not be applied to individuals with VH. Herein, we present a personalized approach for surveillance that may allow an improved shared decision.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024924
003      
CZ-PrNML
005      
20211026134257.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/JU.0000000000001886 $2 doi
035    __
$a (PubMed)34032498
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Martini, Alberto $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
245    10
$a Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy / $c A. Martini, L. Afferi, S. Zamboni, JG. Schultz, C. Lonati, A. Mattei, RJ. Karnes, M. Soligo, A. Stabile, E. Di Trapani, O. De Cobelli, G. Simone, C. Simeone, M. Alvarez-Maestro, G. Gandaglia, A. Gallina, R. Colombo, A. Briganti, F. Montorsi, E. Xylinas, SF. Shariat, M. Moschini
520    9_
$a PURPOSE: Presently, major guidelines do not provide specific recommendations on oncologic surveillance for patients who harbor variant histology (VH) bladder cancer (BCa) at radical cystectomy. We aimed to create a personalized followup scheme that dynamically weighs other cause mortality (OCM) vs the risk of recurrence for VH BCa, and to compare it with a similar one for pure urothelial carcinoma (pUC). MATERIALS AND METHODS: Within a multi-institutional registry, 528 and 1,894 patients with VH BCa and pUC, respectively, were identified. The Weibull regression was used to detect the time points after which the risk of OCM exceeded the risk of recurrence during followup. The risk of OCM over time was stratified based on age and comorbidities, and the risk of recurrence on pathological stage and recurrence site. RESULTS: Individuals with VH had a higher risk of recurrence (recurrence-free survival 30% vs 51% at 10 years, p <0.001) and shorter median time to recurrence (88 vs 123 months, p <0.01) relative to pUC. Among VH, micropapillary variant conferred the greatest risk of recurrence on the abdomen and lungs, and mixed variants carried the greatest risk of metastasizing to bones and other sites compared to pUC. Overall, surveillance should be continued for a longer time for individuals with VH BCa. Notably, patients younger than 60 years with VH and pT0/Ta/T1/N0 at radical cystectomy should continue oncologic surveillance after 10 years vs 6.5 years for pUC individuals. CONCLUSIONS: VH BCa is associated with greater recurrence risk than pUC. A followup scheme that is valid for pUC should not be applied to individuals with VH. Herein, we present a personalized approach for surveillance that may allow an improved shared decision.
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a karcinom z přechodných buněk $x diagnóza $x mortalita $x patologie $x terapie $7 D002295
650    _2
$a cystektomie $7 D015653
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x diagnóza $x epidemiologie $x patologie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a hodnocení rizik $x statistika a číselné údaje $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    _2
$a močový měchýř $x patologie $x chirurgie $7 D001743
650    _2
$a nádory močového měchýře $x diagnóza $x mortalita $x patologie $x terapie $7 D001749
650    12
$a pozorné vyčkávání $7 D057832
655    _2
$a časopisecké články $7 D016428
700    1_
$a Afferi, Luca $u Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Zamboni, Stefania $u Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland $u Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy
700    1_
$a Schultz, Julianne G $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Lonati, Chiara $u Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Mattei, Agostino $u Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Karnes, R Jeffrey $u Department of Urology, Mayo Clinic, Rochester, Minnesota
700    1_
$a Soligo, Matteo $u Department of Urology, Mayo Clinic, Rochester, Minnesota
700    1_
$a Stabile, Armando $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Di Trapani, Ettore $u Department of Urology, European Institute of Oncology, Milan, Italy
700    1_
$a De Cobelli, Ottavio $u Department of Urology, European Institute of Oncology, Milan, Italy $u Department of Oncology and Hematology, University of Milan, Italy
700    1_
$a Simone, Giuseppe $u Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy
700    1_
$a Simeone, Claudio $u Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy
700    1_
$a Alvarez-Maestro, Mario $u Department of Urology, Instituto de Investigación Hospital Universitario Louisiana Paz (IdiPAZ), Madrid, Spain
700    1_
$a Gandaglia, Giorgio $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Gallina, Andrea $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Colombo, Renzo $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Briganti, Alberto $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Montorsi, Francesco $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Xylinas, Evanguelos $u Department of Urology; Bichat Hospital, Paris Descartes University, Paris, France
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Moschini, Marco $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
773    0_
$w MED00003040 $t The Journal of urology $x 1527-3792 $g Roč. 206, č. 4 (2021), s. 885-893
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34032498 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134303 $b ABA008
999    __
$a ok $b bmc $g 1714117 $s 1145431
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 206 $c 4 $d 885-893 $e 20210525 $i 1527-3792 $m The Journal of urology $n J Urol $x MED00003040
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace